Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

141.25
-2.2200-1.55%
Post-market: 141.250.00000.00%19:30 EDT
Volume:1.24M
Turnover:175.17M
Market Cap:14.41B
PE:20.70
High:143.02
Open:142.88
Low:140.34
Close:143.47
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.77
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.90
PE(LYR):30.25

Loading ...

Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades

Stock Track
·
May 06

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Fresenius Medical Care (FMS) and American Well (AMWL)

TIPRANKS
·
May 06

Neurocrine Is Maintained at Outperform by Wedbush

Dow Jones
·
May 06

Neurocrine publishes expert guidance on glucocorticoid tapering after starting Crenessity in CAH

Reuters
·
May 06

Morgan Stanley Raises Price Target on Neurocrine Biosciences to $191 From $185, Keeps Equalweight Rating

MT Newswires Live
·
May 06

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction After Initiating Crenessity® (Crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

THOMSON REUTERS
·
May 06

Neurocrine Biosciences : Oppenheimer Raises Target Price to $230 From $220

THOMSON REUTERS
·
May 06

J.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
May 06

Neurocrine (NBIX) Gets a Buy from Piper Sandler

TIPRANKS
·
May 06

Neurocrine (NBIX) Receives a Buy from Guggenheim

TIPRANKS
·
May 06

Neurocrine Biosciences Inc : Morgan Stanley Raises Target Price to $191.00 From $185.00

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Citigroup Raises Target Price to $246 From $242

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Piper Sandler Raises Target Price to $207 From $190

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Delivers Record Quarter, Eyes 2027

TIPRANKS
·
May 06

Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand

TIPRANKS
·
May 06

Neurocrine Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating

TIPRANKS
·
May 06

Stock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition

Stock Track
·
May 06

Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%

Reuters
·
May 06

Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70

TIPRANKS
·
May 06